-+ 0.00%
-+ 0.00%
-+ 0.00%
ST Huluwa announced that Guangxi Weiwei Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for the simethicone emulsion approved and issued by the State Drug Administration. The drug is a four-class chemical oral emulsion with a specification of 40 mg/ml. Indications include discomfort caused by gastrointestinal gas accumulation, adjuvant medication for abdominal imaging tests, etc. After approval, it is considered to have passed the consistent evaluation of the quality and efficacy of generic drugs. Up to now, the company has invested a total of 4.8997 million yuan in R&D expenses for this product. The approval of this drug will enrich the subsidiary's product line, but there is uncertainty about its sales performance.
Share
Listen to the news
ST Huluwa announced that Guangxi Weiwei Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for the simethicone emulsion approved and issued by the State Drug Administration. The drug is a four-class chemical oral emulsion with a specification of 40 mg/ml. Indications include discomfort caused by gastrointestinal gas accumulation, adjuvant medication for abdominal imaging tests, etc. After approval, it is considered to have passed the consistent evaluation of the quality and efficacy of generic drugs. Up to now, the company has invested a total of 4.8997 million yuan in R&D expenses for this product. The approval of this drug will enrich the subsidiary's product line, but there is uncertainty about its sales performance.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending